These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 1915674)

  • 21. Tissue selectivity of hydroxymethylglutaryl coenzyme A (HMG CoA) reductase inhibitors.
    Sirtori CR
    Pharmacol Ther; 1993 Dec; 60(3):431-59. PubMed ID: 8073070
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types.
    Nègre-Aminou P; van Vliet AK; van Erck M; van Thiel GC; van Leeuwen RE; Cohen LH
    Biochim Biophys Acta; 1997 Apr; 1345(3):259-68. PubMed ID: 9150246
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Different effects of the hypolipidemic drugs pravastatin and lovastatin on the cholesterol biosynthesis of the human ocular lens in organ culture and on the cholesterol content of the rat lens in vivo.
    de Vries AC; Cohen LH
    Biochim Biophys Acta; 1993 Mar; 1167(1):63-9. PubMed ID: 8461334
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tissue selectivity of pravastatin sodium, lovastatin and simvastatin. The relationship between inhibition of de novo sterol synthesis and active drug concentrations in the liver, spleen and testis in rat.
    Koga T; Fukuda K; Shimada Y; Fukami M; Koike H; Tsujita Y
    Eur J Biochem; 1992 Oct; 209(1):315-9. PubMed ID: 1396707
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relative lipophilicities, solubilities, and structure-pharmacological considerations of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors pravastatin, lovastatin, mevastatin, and simvastatin.
    Serajuddin AT; Ranadive SA; Mahoney EM
    J Pharm Sci; 1991 Sep; 80(9):830-4. PubMed ID: 1800703
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comparison of the effect of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors simvastatin, lovastatin and pravastatin on leukaemic and normal bone marrow progenitors.
    Newman A; Clutterbuck RD; Powles RL; Catovsky D; Millar JL
    Leuk Lymphoma; 1997 Feb; 24(5-6):533-7. PubMed ID: 9086443
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors.
    Desager JP; Horsmans Y
    Clin Pharmacokinet; 1996 Nov; 31(5):348-71. PubMed ID: 9118584
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vastatins have a distinct effect on sterol synthesis and progesterone secretion in human granulosa cells in vitro.
    van Vliet AK; van Thiel GC; Naaktgeboren N; Cohen LH
    Biochim Biophys Acta; 1996 Jun; 1301(3):237-41. PubMed ID: 8664334
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potential risk of myopathy by HMG-CoA reductase inhibitors: a comparison of pravastatin and simvastatin effects on membrane electrical properties of rat skeletal muscle fibers.
    Pierno S; De Luca A; Tricarico D; Roselli A; Natuzzi F; Ferrannini E; Laico M; Camerino DC
    J Pharmacol Exp Ther; 1995 Dec; 275(3):1490-6. PubMed ID: 8531120
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in dogs.
    Davis HR; Pula KK; Alton KB; Burrier RE; Watkins RW
    Metabolism; 2001 Oct; 50(10):1234-41. PubMed ID: 11586500
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacology and mechanism of action of the new HMG-CoA reductase inhibitors.
    Sirtori CR
    Pharmacol Res; 1990; 22(5):555-63. PubMed ID: 2126139
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG-CoA reductase.
    Corsini A; Mazzotti M; Raiteri M; Soma MR; Gabbiani G; Fumagalli R; Paoletti R
    Atherosclerosis; 1993 Jun; 101(1):117-25. PubMed ID: 8216498
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lovastatin prevents angiotensin II-induced cardiac hypertrophy in cultured neonatal rat heart cells.
    Oi S; Haneda T; Osaki J; Kashiwagi Y; Nakamura Y; Kawabe J; Kikuchi K
    Eur J Pharmacol; 1999 Jul; 376(1-2):139-48. PubMed ID: 10440099
    [TBL] [Abstract][Full Text] [Related]  

  • 34. RPR 107393, a potent squalene synthase inhibitor and orally effective cholesterol-lowering agent: comparison with inhibitors of HMG-CoA reductase.
    Amin D; Rutledge RZ; Needle SN; Galczenski HF; Neuenschwander K; Scotese AC; Maguire MP; Bush RC; Hele DJ; Bilder GE; Perrone MH
    J Pharmacol Exp Ther; 1997 May; 281(2):746-52. PubMed ID: 9152381
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lovastatin treatment inhibits sterol synthesis and induces HMG-CoA reductase activity in mononuclear leukocytes of normal subjects.
    Stone BG; Evans CD; Prigge WF; Duane WC; Gebhard RL
    J Lipid Res; 1989 Dec; 30(12):1943-52. PubMed ID: 2621421
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hypercholesterolaemia: simvastatin and pravastatin alter cholesterol metabolism by different mechanisms.
    Owens D; Collins P; Johnson A; Tighe O; Robinson K; Tomkin GH
    Biochim Biophys Acta; 1991 Apr; 1082(3):303-9. PubMed ID: 1903069
    [TBL] [Abstract][Full Text] [Related]  

  • 37. On the etiology of subcapsular lenticular opacities produced in dogs receiving HMG-CoA reductase inhibitors.
    Gerson RJ; MacDonald JS; Alberts AW; Chen J; Yudkovitz JB; Greenspan MD; Rubin LF; Bokelman DL
    Exp Eye Res; 1990 Jan; 50(1):65-78. PubMed ID: 2307197
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of a novel squalene epoxidase inhibitor, NB-598, on the regulation of cholesterol metabolism in Hep G2 cells.
    Hidaka Y; Hotta H; Nagata Y; Iwasawa Y; Horie M; Kamei T
    J Biol Chem; 1991 Jul; 266(20):13171-7. PubMed ID: 1649182
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Generalized eczematous skin rash possibly due to HMG-CoA reductase inhibitors.
    Krasovec M; Elsner P; Burg G
    Dermatology; 1993; 186(4):248-52. PubMed ID: 8513188
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vivo and in vitro blood-brain barrier transport of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors.
    Saheki A; Terasaki T; Tamai I; Tsuji A
    Pharm Res; 1994 Feb; 11(2):305-11. PubMed ID: 8165193
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.